Flobufen

Drug Profile

Flobufen

Alternative Names: VUFB 16066

Latest Information Update: 26 Aug 2003

Price : $50

At a glance

  • Originator VUFB
  • Class Analgesics; Antirheumatics; Butyric acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 31 May 1999 Flobufen is available for licensing (http://www.vufb.cz/)
  • 31 Dec 1998 Discontinued - Phase-III for Rheumatic disorders in Czech Republic (unspecified route)
  • 14 Aug 1995 Phase-III clinical trials for Rheumatic disorders in Czech Republic (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top